Curium Pharma

Company snapshot

Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world. We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation. We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to te

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Curium Pharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Curium Pharma.

1. May 26, 2026 Clinical update

   Prostavue — Phase 3

2. May 26, 2026 Clinical update

   64Cu-PSMA I&T — Phase 3

3. May 26, 2026 Clinical update

   64Cu-PSMA I&T — Phase 3

View all clinical trial activity →

• What is Curium Pharma?

  Curium Romania S.R.L is a pharma organization headquartered in EU. Primary therapeutic focus areas include Prostate cancer. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sou

• Is Curium Pharma publicly traded?

  Curium Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Curium Pharma develop or market?

  No drug profiles are currently linked to Curium Pharma. Pipeline programs may still list investigational assets.

• What are the latest developments for Curium Pharma?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Curium Pharma focus on?

  Curium Pharma focuses on Prostate cancer based on our analysis of their pipeline programs and drug development activities.